Intravenous immunoglobulin induced - Nephropathy: A complication of IVIG therapy

被引:0
|
作者
Ahsan, N [1 ]
机构
[1] Penn State Univ, Coll Med, Div Nephrol & Hypertens, Dept Med, Hershey, PA 17033 USA
关键词
IVIG; intravenous immunoglobulin; acute renal failure; osmotic nephrosis;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Since the early 1950s, intravenous immunoglobulin (MG) preparations are being used in the treatment of hematologic, neurologic, nephrologic, autoimmune, and immunodeficiency disorders. Infusion of MG preparations may cause osmotic-induced acute renal failure, Despite the fact that this entity has been reported previously, it is not a widely appreciated complication. A total of 22 reports involving 52 patients in whom renal failure occurred in association with MG infusion. The patients' ages ranged from 20 to 82 years. Thirty patients had preexisting renal insufficiency. Rise in serum creatinine was noted after 1-10 days of MG infusion and creatinine returned to baseline within 2-60 days of discontinuation. One developed end stage renal disease. There were four fatalities related to complications of renal failure. Histopathology of renal tissue showed osmotically induced tubular injury (5 patients), tubular vacuolization (2 patients), tubulointerstitial infiltrate (1 patient), and cryoglobulin deposits (1 patient). There appears to be no direct relationship between the development of acute renal failure and the type of MG. However, underlying renal-insufficiency increases the risk of renal failure, In view of the increasing use of MG preparations in medicine, it is imperative that clinicians be aware of this unusual form renal injury.
引用
收藏
页码:157 / 161
页数:5
相关论文
共 50 条
  • [1] Intravenous immunoglobulin (IVIG) as rescue therapy for BK virus nephropathy
    Vu, Don
    Shah, Tariq
    Naraghi, Robert
    Hutchinson, Ian V.
    Min, David I.
    [J]. PHARMACOTHERAPY, 2012, 32 (10): : E246 - E246
  • [2] Safety of intravenous immunoglobulin (IVIG) therapy
    Katz, Uriel
    Achiron, Anat
    Sherer, Yaniv
    Shoenfeld, Yehuda
    [J]. AUTOIMMUNITY REVIEWS, 2007, 6 (04) : 257 - 259
  • [3] INTRAVENOUS IMMUNOGLOBULIN (IVIG) FOR THE THERAPY OF AUTOIMMUNE DISORDERS
    SCHWARTZ, SA
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 1990, 10 (02) : 81 - 89
  • [4] INTRAVENOUS IMMUNOGLOBULIN (IVIG) THERAPY OF NEONATAL SEPSIS
    WEISMAN, LE
    STOLL, B
    KUESER, T
    RUBIO, T
    FRANK, G
    HEIMAN, H
    SUBRAMANIAN, S
    HANKINS, C
    HEMMING, V
    FISCHER, GW
    [J]. PEDIATRIC RESEARCH, 1990, 27 (04) : A277 - A277
  • [5] USE OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) THERAPY IN ADULTS
    HERROD, HG
    [J]. ALLERGY PROCEEDINGS, 1994, 15 (06): : 309 - 312
  • [6] Intravenous Immunoglobulin Therapy (IvIg) Induced Posterior Reversible Encephalopathy Syndrome (PRES)
    Khosa, Shaweta
    Khosa, Gurveer Singh
    Mishra, Shri Kant
    Rao, Neal
    Freundlich, Robert
    [J]. ANNALS OF NEUROLOGY, 2022, 92 : S72 - S72
  • [7] Intravenous immunoglobulin (IVIG)
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2006, 48 (1249): : 101 - 103
  • [8] Intravenous immunoglobulin (IVIG) in the vanguard therapy of Systemic Sclerosis
    Gomes, Joao Pedro
    Santos, Lelila
    Shoenfeld, Yehuda
    [J]. CLINICAL IMMUNOLOGY, 2019, 199 : 25 - 28
  • [9] INTRAVENOUS IMMUNOGLOBULIN (IVIG) THERAPY OF NEONATAL ALLOIMMUNE GRANULOCYTOPAENIA
    JARVENPAA, AL
    RAJANTIE, J
    [J]. ACTA PAEDIATRICA SCANDINAVICA, 1991, 80 (8-9): : 885 - 886
  • [10] Virus reactivation and intravenous immunoglobulin (IVIG) therapy of drug-induced hypersensitivity syndrome
    Kano, Y
    Inaoka, M
    Sakuma, K
    Shiohara, T
    [J]. TOXICOLOGY, 2005, 209 (02) : 165 - 167